ArticleEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2023
Clinical outcomes of transcatheter mitral valve replacement: two-year results of the CHOICE-MI Registry.
Article in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Mitral Regurgitation in Contemporary Practice: From Diagnosis to Management.Reviews in cardiovascular medicine · 2026Review
- Five-year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation: results from the Tendyne Expanded Clinical Study.ESC heart failure · 2026Article
- Transapical transcatheter mitral valve implantation in a patient with mitral annular defect due to a patch dehiscence after aortic valve replacement: a case report.European heart journal. Case reports · 2026Article
- Effect of Age on Short-Term Readmissions Following Transcatheter Edge-to-Edge Repair of the Mitral Valve.Structural heart : the journal of the Heart Team · 2026Article
- 5-Year Follow-Up After Transcatheter Mitral Valve Replacement Using the Cardiovalve System.JACC. Case reports · 2026Article
- Surgical Explant of Degenerated Transcatheter Valves: A New Type of Threat?Interdisciplinary cardiovascular and thoracic surgery · 2026Review
- Special topics: heart failure-related cardiogenic shock, valvular heart disease and end-stage renal disease. Part 4 of the International Expert Opinion Series on Acute Heart Failure Management.Heart failure reviews · 2025Review
- Transesophageal Echocardiography in Transcatheter Mitral Valve Replacement.Journal of clinical medicine · 2025Review
- Evolving Perspectives in Surgery for Mitral Regurgitation: Why Sex Matters.Journal of the American Heart Association · 2025Review
- Impact of pulmonary hypertension dynamics and residual mitral regurgitation shortly after M-TEER on long-term outcomes: insights from a prospective registry.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Transcatheter Mitral Valve Replacement Using Contemporary Dedicated Devices: A Systematic Review and Meta-Analysis.Structural heart : the journal of the Heart Team · 2025Article
- Functional Mitral Regurgitation in the Transcatheter Era: Diagnostic and Therapeutic Pathways.Journal of personalized medicine · 2025Review
- Transcatheter Structural Heart Interventions in Women.Current cardiology reports · 2025Review
- A Novel Self-Expanding Transcatheter Mitral Valve with Dual Annulus/Valve Diameter.Journal of functional biomaterials · 2025Article
- An Imaging-Based Marker to Refine Risk Stratification for Transcatheter Mitral Valve Replacement.Journal of clinical medicine · 2025Article
- Contemporary Outcomes and Trends for the Transseptal Mitral Valve-in-Valve Procedure Using Balloon Expandable Transcatheter Valves in the United States.Circulation · 2024Article
- Papillary Muscle Maneuvers: Pathophysiology-based Approach in Secondary Mitral Regurgitation.Reviews in cardiovascular medicine · 2024Review
- Clinical outcomes and predictors of transapical transcatheter mitral valve replacement: the Tendyne Expanded Clinical Study.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024Article
- Left and Right Ventricular Hemodynamic Response After Transcatheter Mitral Valve Replacement.Structural heart : the journal of the Heart Team · 2024Article
- CardioTwins: case report of a transcatheter mitral and tricuspid valve implantation in one patient.European heart journal. Case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 20 institutions in 11 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter mitral valve replacement (TMVR) using dedicated devices is an alternative therapy for high-risk patients with symptomatic mitral regurgitation (MR).
aimsThis study aimed to assess the 2-year outcomes and predictors of mortality in patients undergoing TMVR from the multicentre CHOICE-MI Registry.
methodsThe CHOICE-MI Registry included consecutive patients with symptomatic MR treated with 11 different dedicated TMVR devices at 31 international centres. The investigated endpoints included mortality and heart failure hospitalisation rates, procedural complications, residual MR, and functional status. Multivariable Cox regression analysis was applied to identify independent predictors of 2-year mortality.
resultsA total of 400 patients, median age 76 years (interquartile range [IQR] 71, 81), 59.5% male, EuroSCORE II 6.2% (IQR 3.8, 12.0), underwent TMVR. Technical success was achieved in 95.2% of patients. MR reduction to ≤1+ was observed in 95.2% at discharge with durable results at 1 and 2 years. New York Heart Association Functional Class had improved significantly at 1 and 2 years. All-cause mortality was 9.2% at 30 days, 27.9% at 1 year and 38.1% at 2 years after TMVR. Chronic obstructive pulmonary disease, reduced glomerular filtration rate, and low serum albumin were independent predictors of 2-year mortality. Among the 30-day complications, left ventricular outflow tract obstruction, access site and bleeding complications showed the strongest impact on 2-year mortality.
conclusionsIn this real-world registry of patients with symptomatic MR undergoing TMVR, treatment with TMVR was associated with a durable resolution of MR and significant functional improvement at 2 years. Two-year mortality was 38.1%. Optimised patient selection and improved access site management are mandatory to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.